The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disrupted

Ninety-seven percent of care partners reported that agitation negatively impacted their loved one’s quality of life, and three in four wish they had recognized symptoms sooner

Results from the survey were recently presented at Psych Congress 2026 in New Orleans, Louisiana

Survey conducted by The Harris Poll and in collaboration with CaringKind

NEW YORK, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today, in connection with World Alzheimer’s Day, announced results of the Shared Goals: Navigating Alzheimer's Agitation survey that highlight the profound impact that symptoms of agitation can have on people with Alzheimer’s disease and their family care partners.

The Shared Goals survey of 751 adults who currently provide care to a loved one with Alzheimer’s disease was conducted online by The Harris Poll, with input from CaringKind, a leading expert on Alzheimer’s and dementia caregiving with over 40 years of experience, and sponsored by Axsome. It is among the largest and most recent surveys of care partners of people living with Alzheimer’s disease agitation. The Shared Goals survey results were presented at Psych Congress 2026 in New Orleans, Louisiana, on September 17 and 18, 2026.